Effect of exenatide, sitagliptin, or glimepiride on β-cell secretory capacity in early type 2 diabetes.

ABSTRACT:

Objective

Agents that augment GLP-1 effects enhance glucose-dependent β-cell insulin production and secretion and thus are hoped to prevent progressive impairment in insulin secretion characteristic of type 2 diabetes (T2D). The purpose of this study was to evaluate GLP-1 effects on β-cell secretory capacity, an in vivo measure of functional β-cell mass, early in the course of T2D.

Research design and methods

We conducted a randomized controlled trial in 40 subjects with early T2D who received the GLP-1 analog exenatide (n = 14), the dipeptidyl peptidase IV inhibitor sitagliptin (n = 12), or the sulfonylurea glimepiride (n = 14) as an active comparator insulin secretagogue for 6 months. Acute insulin responses to arginine (AIRarg) were measured at baseline and after 6 months

SUBMITTER: Gudipaty L 

PROVIDER: S-EPMC4140159 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature